Sanjeev Pathak

Sanjeev Pathak

Auto-generated profile, based on publicly available information

Sanjeev Pathak

Alkermes, Inc., Waltham, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
JZJohn M Zajecka
John M Zajecka
ASArielle D Stanford
Arielle D Stanford
AMASLI MEMISOGLU
ASLI MEMISOGLU
WMWilliam F Martin
William F Martin
SPSanjeev Pathak
Sanjeev Pathak
Background: The endogenous opioid system is a fundamental regulator of mood in humans. Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major depressive disorder. We present here a third phase III study of different design. Methods: Adult patients with major depressive disorder and inadequate response to antidepressant therapy were enrolled in this double-blind, placebo-controlled, placebo run-in study to evaluate the efficacy, safety, and tolerability of adjunctive BUP/SAM 2 mg/2 mg. Patients with baseline Hamilton Depression Rating Scale score ≥20 received double-blind placebo in addition to background antidepressant therapy for 4 weeks. Nonresponders were randomized to receive adjunctive BUP/SAM 2 mg/2 mg or placebo for 6 weeks. The primary end point was change in Montgomery–Åsberg Depression Rating Scale (MADRS)-10 total score from randomization at baseline to the end of the 6-week treatment period. Results: Least-squares mean change in MADRS-10 score at end of treatment was -4.8 (SE 0.67) in the BUP/SAM 2 mg/2 mg group and -4.6 (SE 0.66) in the placebo group (mean difference -0.3 [SE 0.95], P=0.782). There were no differences in MADRS-based response or remission rates. Overall, 42.9% of the BUP/SAM 2 mg/2 mg group and 34.5% of the placebo group experienced at least one treatment-emergent adverse event during the 6-week treatment period, most of which were mild or moderate in severity. There were no clinically important changes in laboratory parameters, weight, or vital signs and no evidence of abuse potential during treatment or opiate-withdrawal symptoms post treatment. Conclusion: Efficacy results in FORWARD-3 measured by change in MADRS-10 score did not meet the primary end point, but postbaseline improvement in MADRS-10 in the BUP/SAM 2 mg/2 mg group was consistent with that seen in previously reported trials. BUP/SAM 2 mg/2 mg was well tolerated.

26 November 2018 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SPSanjeev Pathak
Sanjeev Pathak
BVBradley Vince
Bradley Vince
DKDebra Kelsh
Debra Kelsh
BSBeatrice Setnik
Beatrice Setnik
NNNarinder Nangia
Narinder Nangia
EEElliot Ehrich
Elliot Ehrich

13 August 2018 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SPSanjeev Pathak
Sanjeev Pathak
BVBradley Vince
Bradley Vince
DKDebra Kelsh
Debra Kelsh
MSMegan J. Shram
Megan J. Shram
BSBeatrice Setnik
Beatrice Setnik
EEElliot Ehrich
Elliot Ehrich

1 July 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
WCWiesław Jerzy Cubała
Wiesław Jerzy Cubała
ABAna Berrio
Ana Berrio
KCKatherine Chi-Burris
Katherine Chi-Burris
GAGustavo Alva
Gustavo Alva
LCLambros Chrones
Lambros Chrones
SPSanjeev Pathak
Sanjeev Pathak
Background: An 8-week, phase 3b, randomized, placebo-controlled trial demonstrated that pimavanserin, a selective 5HT 2A inverse agonist, is generally well tolerated in elderly patients with neuropsychiatric symptoms related to neurodegenerative disease (NDD). Objective: This open-label extension (OLE) study assessed the long-term safety and tolerability of pimavanserin. Methods: Patients from the antecedent double-blind (DB) trial who were treated with oral pimavanserin (34 mg/day) or placebo were enrolled. The safety analysis population included all patients who received ≥1 dose of pimavanserin. The primary endpoint was treatment-emergent adverse events (TEAEs). Exploratory endpoints included change from baseline in Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A), Mini-Mental State Examination (MMSE), Clinical Global Impression-Severity (CGI-S), EuroQoL 5-Dimension 5-Level (EQ-5D-5L), and Sleep Disorders Inventory (SDI) scores. Results: Patients (N = 595; mean age, 72.2 years) received pimavanserin treatment (mean exposure, 312.4 days). Most patients (95.3%) had dementia (68.7% of whom had Alzheimer's disease), and 70.6% were concomitantly treated with anti-dementia drugs. TEAEs occurred in 238 (40.0%) patients, and 37 (6.2%) had a serious TEAE; 1 (0.2%) was pimavanserin-related. TEAEs resulted in treatment discontinuation in 39 (6.6%) patients. Fatal TEAEs occurred in 11 (1.8%) patients (none considered related to pimavanserin). The mean (standard error) change from DB baseline to OLE Week 52 in MMSE, ESRS-A, CGI-S, EQ-5D-5L, and SDI scores was +0.9 (0.21), −0.3 (0.22), −1.0 (0.05), + 10.7 (0.87), and −0.9 (0.07), respectively. No patients reported suicidal behavior. Conclusions: Pimavanserin was generally well tolerated in frail older adults and elderly patients with neuropsychiatric symptoms related to NDD for up to 52 weeks of treatment.

27 November 2024 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
SRSapna Rao
Sapna Rao
JFJoan Forns
Joan Forns
HDHeather E Danysh
Heather E Danysh
BCBrian Calingaert
Brian Calingaert
CDColleen Dempsey
Colleen Dempsey
JLJ Bradley Layton
J Bradley Layton
Background: While some literature on clinical outcomes in persons with dementia-related psychosis exists, little is known regarding Alzheimer's disease–related psychosis (ADP). Objective: Describe demographic/clinical characteristics of adults with ADP and estimate incidence of clinical events by antipsychotic treatment status. Methods: This cohort study identified adults ≥65 years with Alzheimer's disease and incident psychosis (US Medicare database [2013–2018]) and no prior exposure to antipsychotics. Two nonmutually exclusive ADP subcohorts included: patients who initiated treatment with antipsychotic medications (antipsychotic users) and those who remained untreated (antipsychotic nonusers). Baseline characteristics were evaluated before psychosis diagnosis in untreated patients and before antipsychotic initiation in treated patients. Incidence rates were estimated for falls and fractures (composite and separately), seizure/epilepsy (new onset and any), and mortality. Results: 145,333 ADP antipsychotic nonusers and 49,452 antipsychotic users were identified. Both cohorts had similar baseline demographics; however, antipsychotic users versus nonusers had higher baseline skilled nursing facility use (40.3% and 27.8%), mood (72.7% and 62.1%) and anxiety (70.9% and 57.3%) disorders, falls/fractures (39.5% and 33.8%), urinary tract infections (55.1% and 47.0%), and frailty index scores (76.0% and 69.7%). Crude incidence rates (95% confidence interval)/100 person-years in antipsychotic users and nonusers were 70.0 (68.9–71.2) and 55.8 (55.4–56.1) (falls/fractures composite), 69.0 (67.9–70.1) and 54.9 (54.5–55.2) (falls), 38.6 (38.1–39.0) and 33.0 (32.7–33.2) (mortality), and 45.8 (44.9–46.7) and 54.2 (53.9–54.6) (any seizure/epilepsy). Conclusions: Antipsychotic initiators with ADP had a higher burden of some baseline comorbidities; experienced higher incidence of falls, fractures, and mortality; and had lower incidence of seizure/epilepsy than antipsychotic nonusers.

5 May 2026 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
EBEthan S. Burstein
Ethan S. Burstein
RORoger Olsson
Roger Olsson
NSNiklas Skold
Niklas Skold
KJKarl Erik Jansen
Karl Erik Jansen
MAMarc Azar
Marc Azar
SPSanjeev Pathak
Sanjeev Pathak
Pimavanserin was the first US Food and Drug Administration approved antipsychotic drug that does not block D2 dopamine receptors at therapeutic doses. Pimavanserin is a selective 5-HT2A receptor inverse agonist that reduces the frequency of hallucinations and delusions associated with Parkinson disease. Despite these attributes, pimavanserin prolongs the QT interval at therapeutic doses, limiting the dose to 34 mg. In addition, pimavanserin has a 57-hour half-life, and reaches steady state in approximately 12 days. ACP-204 was identified as a compound with subnanomolar affinity in radioligand binding assays, and subnanomolar inverse agonist and antagonist potency at 5-HT2A receptors in cell-based functional assays. ACP-204 had 13-fold less affinity for 5-HT2C receptors in radioligand binding, and 30- to 100-fold less potency at 5-HT2C in the functional assays, and was over 1000-fold selective against over 70 other targets. ACP-204 had 9-fold lower potency inhibiting human ether-à-go-go-related gene than pimavanserin, and lower potency at Cav1.2 L-type calcium and Nav1.5 sodium channels, all channels associated with cardiovascular function. ACP-204 was active in 3 rodent models of schizophrenia, was orally active, and potently engaged with central 5-HT2A receptors in nonhuman primates. Long-term toxicity studies demonstrated wide safety margins, and pharmacokinetic modeling predicted a 14.7 to 21.7 hours half-life in humans. It is anticipated that reducing the potential for QT prolongation will allow greater dosing flexibility with ACP-204 compared with pimavanserin; additionally, a shorter half-life may provide faster onset of action because of plasma concentrations reaching steady state sooner. ACP-204 is currently being evaluated for efficacy and safety in Alzheimer disease psychosis and Lewy body dementia psychosis. SIGNIFICANCE STATEMENT: Psychotic disorders remain a major source of burden and disability worldwide, with current treatments limited by inadequate efficacy or significant side effects. ACP-204 is a novel 5-HT2A receptor inverse agonist/antagonist being evaluated clinically for its potential to treat Alzheimer disease psychosis and Lewy body dementia psychosis. Comprehensive nonclinical evaluations shown herein demonstrate that ACP-204 has optimized pharmacodynamic properties resulting in a favorable safety/tolerability profile, a broad therapeutic index, and promising effectiveness.